德摩膚爽乳膏

Country: Tajwan

Lingwa: Ċiniż

Sors: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

Ingredjent attiv:

MOMETASONE FUROATE

Disponibbli minn:

百德健有限公司 臺北市中山區民生東路一段58號11樓 (28843592)

Kodiċi ATC:

D07AC13

Għamla farmaċewtika:

乳膏劑

Kompożizzjoni:

MOMETASONE FUROATE (6804002310) MG

Unitajiet fil-pakkett:

鋁管裝

Klassi:

製　劑

Tip ta 'preskrizzjoni:

須由醫師處方使用

Manifatturat minn:

DONGKOO BIO & PHARMA. CO., LTD. 18, JEYAKGONGDAN 2-GIL, HYANGNAM-EUP, HWASEONG-SI, GYEONGGI-DO, KOREA KR

Żona terapewtika:

mometasone

Indikazzjonijiet terapewtiċi:

對類固醇具有感受性之皮膚病所引起之炎性反應及搔癢之緩解。

Sommarju tal-prodott:

註銷日期: 2022/07/11; 註銷理由: 許可證已逾有效期; 有效日期: 2020/11/09; 英文品名: DERMOTASONE cream

L-istatus ta 'awtorizzazzjoni:

已註銷

Data ta 'l-awtorizzazzjoni:

2005-11-09

Fuljett ta 'informazzjoni

DERMOTASONE CREAM
【
APPEARANCE
】 White cream
【
COMPOSITION
】
One gram contains :
Mometasone Furoate -------------------------------------1.0mg
【
INDICATION
】
Relief of the inflammatory and pruritic manifestations of
corticosteroid responsive dermatoses.
【
DOSAGE AND ADMINISTRATION
】
1. Apply a thin film of Dermotasone Cream 0.1% to the affected skin
areas once daily.
2. Dermotasone cream 0.1% should not be used with occlusive dressings
unless directed by a physician.
【
CAUTION
】
1. Contra indications
1) Patients who have skin infectious diseases; bacteria (tuberculosis,
syphilis, etc), fungus (candida,
dermatophyte), virus (herpes zoster, herpes simplex, chickenpox,
vaccinia, etc), animal (scabies,
phthiriasis pubis, etc).
2) Patients who have been experienced hypersensitivity for this
medicine’s ingredients.
3) Eczematous external otitis patients who have drum membrane
perforation.
4) Patients who have ulcer, burn more than second degree or chilblain.
5) Perioral dermatitis, general acne, rosacera patients.
6) Patients suffering from perianal and genital pruritis.
7) Baby under the age of 2 years.
2. General cautions.
1) Do not use this medicine for eczema, dermatitis accompanied with
skin infection. But if this medicine must
be used in an unavoidable case, treat the symptoms with antibacterial
agent (systemic administration),
antifungal agent first or consider of combined treatment.
2) Systemic absorption of local corticoids may make adverse HPA axis
suppression, cushing’s syndrome,
hyperglycemia, glucosuria, etc to some patients and the patients
treated under wide ranged body surface
or ODT with local corticoids shall be periodically checked about HPA
axis suppression by plasma cortisol
concentrations, measuring cortisol released from urea or ACTH stimulus
test.
3) If HPA axis is restrained by systemic absorption of local
corticoid, stop using medication, reduce the
frequency of administration, and replace to weak activity corticoid.
Generally, hypothalamic pituitary
adrenal axis functi